Selexipag Research for PAH
Not Applicable
Recruiting
- Conditions
- Pulmonary arterial hypertension
- Registration Number
- JPRN-jRCT1051220173
- Lead Sponsor
- Ogo Takeshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
PAH patients treated with selexipag between November 21, 2016, and July 31, 2022, at the Division of Pulmonary Circulation, National Cerebral and Cardiovascular Center (including PAH patients who were introduced to selexipag at other hospitals and referred to National Cerebral and Cardiovascular Center)
Exclusion Criteria
Patients who have requested that their information not be used by the patient or his/her family
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in PVR between baseline and 52 weeks after Selexipag administration
- Secondary Outcome Measures
Name Time Method